Kathleen N. Moore, MD | Authors

August 16, 2017

Kathleen N. Moore, MD, assistant professor in the section of gynecologic oncology and director of the Oklahoma TSET Phase I Clinical Trials Program at the University of Oklahoma Health Sciences Center, discusses challenges with PARP inhibitors in ovarian cancer.

June 05, 2017

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses results of an ongoing clinical trial exploring mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant epithelial ovarian cancer patients, during the 2017 ASCO Annual Meeting.

March 16, 2017

Kathleen N. Moore, MD, assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.